CastleKnight Management’s Moderna MRNA Stock Holding History

CastleKnight Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,500	Closed	-$431K	–	275
2022 Q1	$431K	Buy	+2,500	New	+$421K	0.06%	187

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CastleKnight Management's MRNA Position: Q2 2022 in Review

CastleKnight Management sold out of Moderna (MRNA) in Q2 2022, closing a stake of 2,500 shares — an estimated $431K sold.

CastleKnight Management first reported a position in MRNA in Q1 2022 and held it in 1 quarter. The position peaked at $431K in Q1 2022. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

CastleKnight Management reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
CastleKnight Management sold 2,500 Moderna shares in Q2 2022, an estimated $431K.
CastleKnight Management first reported a position in Moderna in Q1 2022 and held it in 1 quarter.
CastleKnight Management's Moderna position peaked at $431K in Q1 2022.
981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on CastleKnight Management's 13F filing for Q2 2022, filed 15 Aug 2022.